Details of Disease

General Information of Disease (ID: DISRZ2R6)

Disease Name Human immunodeficiency virus-1 infection
Disease Class 1C60-1C62: Human immunodeficiency virus disease
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISRZ2R6: Human immunodeficiency virus-1 infection
ICD Code
ICD-11
ICD-11: 1C62
ICD-10
ICD-10: B20-B24
ICD-9
ICD-9: 42
Expand ICD-9
42

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 6 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Darunavir DMN3GCH Approved Small molecular drug [1]
Etravirine DMGV8QU Approved Small molecular drug [2]
Ibalizumab DMV67QO Approved Antibody [3]
Lamivudine DMI347A Approved Small molecular drug [4]
Lenacapavir DMW7TZV Approved Small molecular drug [5]
Sipuleucel-T DMSEXNP Approved NA [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 53 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Remune DMFLECG Phase 3 NA [7]
RemuneX DMCJUL5 Phase 3 NA [7]
PRO 140 DMCGK6X Phase 2/3 Antibody [8]
VM1500A DM9YSSY Phase 2/3 Small molecule [9]
AGS-004 DMP2U95 Phase 2 NA [10]
APH-0812 DM756GE Phase 2 NA [11]
Autologous dendritic cell vaccine DM5UEP2 Phase 2 NA [12]
BMS-955176 DMMEAGO Phase 2 NA [13]
Cenicriviroc DM4V8WF Phase 2 Small molecular drug [1]
DermaVir DM3OC9W Phase 2 Vaccine [14]
GSK2838232 DMCIGRW Phase 2 Small molecular drug [15]
GSK3810109 DMV3TO4 Phase 2 Antibody [16]
HGTV43 DM0LA6E Phase 2 Antisense drug [1]
HIV-1 vaccine DMAEI8G Phase 2 NA [17]
Lefitolimod DMS6E9J Phase 2 NA [18]
OBP-601 DMVXZC4 Phase 2 Small molecular drug [19]
UB-421 DMY0ZK7 Phase 2 NA [20]
Vacc-4x DMDAKZW Phase 2 Vaccine [21]
Cal-1 DMUZIRY Phase 1/2 NA [22]
MaC46/M87o DMIRG15 Phase 1/2 NA [23]
Multiclade DNA recombinant adenovirus-5 (rAd5) vaccine DM2UQS3 Phase 1/2 NA [24]
SB-728-mR-T DMBIGTU Phase 1/2 Cell therapy [25]
TUTI-16 DMFF0PQ Phase 1/2 NA [26]
Ad5-ENVA-48 DMMBQV3 Phase 1 Vaccine [27]
AFO-18 DMSX24U Phase 1 Vaccine [28]
Anti-PD-L1 DM0UL47 Phase 1 Antibody [29]
EP HIV-1090 vaccine DMREGCT Phase 1 NA [30]
EP-1043 DMOVIZ1 Phase 1 NA [31]
EP1090 DMLS7LA Phase 1 NA [30]
GOVX-B01 DMQZZAV Phase 1 Vaccine [32]
GS-1720 DMARVRW Phase 1 NA [33]
GS-5894 DM1PXAU Phase 1 Small molecule [33]
GS-6212 DM98MG0 Phase 1 Small molecule [34]
GS-8588 DMMMQ1Z Phase 1 NA [34]
HIV multiantigen vaccine DM19WLT Phase 1 NA [35]
ITX-5061 DM702MU Phase 1 Small molecular drug [36]
KD-247 DM6IO6M Phase 1 NA [37]
Lentiviral RNAi therapy DMGVOBY Phase 1 NA [38]
MazF gene therapy DMSZ8HT Phase 1 NA [39]
MGD014 DMZN5QX Phase 1 Antibody [40]
MK-1972 DM28STR Phase 1 NA [41]
MK-8504 DMHTWBL Phase 1 Small molecular drug [42]
MK-8527 DM208B5 Phase 1 NA [43]
MK-8558 DMOW1NS Phase 1 NA [44]
MK-8583 DMQHPME Phase 1 Small molecular drug [45]
mRNA-1644 DMSZBZI Phase 1 Vaccine [46]
Replication-defective HIV vaccine DM81GRZ Phase 1 NA [1]
Replication-defective HIV-1 vaccine DMXQPN7 Phase 1 NA [47]
SAV-001 DMC0UG8 Phase 1 NA [48]
SB-728mR-HSPC DML3WDJ Phase 1 Cell therapy [49]
Tak-220 DMW10HM Phase 1 Small molecular drug [50]
TMB-365 DMH3E5C Phase 1 Antibody [51]
VRC07-523LS DM0S9OT Phase 1 Antibody [52]
------------------------------------------------------------------------------------
⏷ Show the Full List of 53 Drug(s)
This Disease is Treated as An Indication in 16 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
GW873140 DMG6TS2 Discontinued in Phase 3 Small molecular drug [53]
Trecovirsen sodium DM2P0CR Discontinued in Phase 2 NA [54]
Gem 92 DM4ZDVY Discontinued in Phase 1 Antisense drug [55]
PN-355 DMFKC7L Discontinued in Phase 1 NA [56]
BAY-Z-4305 DMZGFM6 Terminated NA [57]
BMS-186318 DMKZ3PW Terminated Small molecular drug [58]
CGP-70726 DMRLXC3 Terminated NA [59]
CNI-H0294 DMBNDW4 Terminated Small molecular drug [60]
K-42 DM5PGNI Terminated Small molecular drug [61]
MEN-10690 DM57S3D Terminated Small molecular drug [62]
MEN-10880 DMKS1W0 Terminated Small molecular drug [63]
MEN-10979 DM6UYN1 Terminated Small molecular drug [64]
PD-153103 DMVEXID Terminated NA [65]
R-71762 DMKJMCS Terminated Small molecular drug [66]
SB-206343 DMYFE23 Terminated Small molecular drug [67]
SR-11335 DMR45CM Terminated NA [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)
This Disease is Treated as An Indication in 14 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
4-ethynyl-2-fluoro-deoxyadenosine DMSKZ6F Investigative NA [69]
AGX-1009 DMK1ZJL Investigative NA [69]
APD DM0E3YY Investigative NA [69]
AS-337 DMEN8HM Investigative NA [69]
BMS-599793 DM2SFO4 Investigative NA [69]
BRU-83-92 DMEYMJK Investigative NA [69]
CD4-BFFI DMSTUWY Investigative NA [69]
CMPD-167 DM9IPH4 Investigative Small molecular drug [70]
GRL-0036A DM0MTYR Investigative Small molecular drug [69]
GSK-812397 DMT98PA Investigative Small molecular drug [71]
IQP-0410 DMIYON5 Investigative NA [69]
Molecule 25 DMDSJH1 Investigative NA [69]
QNL-111 DM3H7RP Investigative NA [69]
VDA, HIV-1 DM5YRCQ Investigative NA [69]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
3 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 761065.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215973.
6 ClinicalTrials.gov (NCT01133704) Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer. U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT03902522) PRO 140 in Treatment-Experienced HIV-1 Subjects. U.S. National Institutes of Health.
9 ClinicalTrials.gov (NCT05204394) Multicenter, Open-label, Randomized, Active Control Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy. U.S.National Institutes of Health.
10 ClinicalTrials.gov (NCT01069809) Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption. U.S. National Institutes of Health.
11 Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
12 A therapeutic dendritic cell vaccine for HIV-1 infection controls virus replication temporarily. University of Barcelona report.
13 ClinicalTrials.gov (NCT02415595) Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults. U.S. National Institutes of Health.
14 ClinicalTrials.gov (NCT00711230) Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naive Patients (GIEU006). U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT03045861) Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults. U.S. National Institutes of Health.
16 ClinicalTrials.gov (NCT04871113) A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults. U.S. National Institutes of Health.
17 ClinicalTrials.gov (NCT02336074) Research In Viral Eradication of HIV Reservoirs. U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT03837756) Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN). U.S. National Institutes of Health.
19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024698)
20 ClinicalTrials.gov (NCT01668043) Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT01712256) Re-boosting of HIV-1 Infected Subjects With Vacc-4x. U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT01734850) Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection. U.S. National Institutes of Health.
23 Creating genetic resistance to HIV. Curr Opin Immunol. 2012 Oct;24(5):625-32.
24 A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis. 2010 Feb 15;201(4):600-7.
25 ClinicalTrials.gov (NCT02225665) A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning. U.S.National Institutes of Health.
26 ClinicalTrials.gov (NCT01335191) Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001). U.S. National Institutes of Health.
27 ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
28 ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health.
29 ClinicalTrials.gov (NCT01455103) Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma. U.S. National Institutes of Health.
30 ClinicalTrials.gov (NCT00532974) A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART). U.S. National Institutes of Health.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022871)
32 Clinical pipeline report, company report or official report of GeoVax
33 ClinicalTrials.gov (NCT05585307) An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1. U.S.National Institutes of Health.
34 Clinical pipeline report, company report or official report of Gilead
35 ClinicalTrials.gov (NCT00629057) A Safety Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer. U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT01165359) Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults. U.S. National Institutes of Health.
37 ClinicalTrials.gov (NCT00917813) A Study of Anti-HIV Monoclonal Antibody KD-247. U.S. National Institutes of Health.
38 Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
39 Clinical pipeline report, company report or official report of Takara Bio.
40 ClinicalTrials.gov (NCT03570918) MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. U.S. National Institutes of Health.
41 ClinicalTrials.gov (NCT01353898) Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003). U.S. National Institutes of Health.
42 ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health.
43 ClinicalTrials.gov (NCT03615183) A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002). U.S. National Institutes of Health.
44 ClinicalTrials.gov (NCT03859739) Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naive HIV-1 Infected Participants (MK-8558-002). U.S. National Institutes of Health.
45 ClinicalTrials.gov (NCT03552536) MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002). U.S. National Institutes of Health.
46 ClinicalTrials.gov (NCT05414786) A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health. U.S.National Institutes of Health.
47 ClinicalTrials.gov (NCT01428596) Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects. U.S. National Institutes of Health.
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035458)
49 ClinicalTrials.gov (NCT02500849) A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients. U.S.National Institutes of Health.
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 800).
51 ClinicalTrials.gov (NCT04027387) Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants. U.S. National Institutes of Health.
52 ClinicalTrials.gov (NCT03735849) Evaluating the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants. U.S. National Institutes of Health.
53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 805).
54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002794)
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008217)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005490)
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012173)
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004898)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007747)
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009055)
61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011049)
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008240)
63 [Abstract Book Vol. 2, International Conference on AIDS (10th: 1994: Yokohama, Japan)], International AIDS Society, 1994.
64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008234)
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005066)
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012403)
67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005565)
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003736)
69 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
70 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3651).
71 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
72 ClinicalTrials.gov (NCT01565850) Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. U.S. National Institutes of Health.
73 ClinicalTrials.gov (NCT00043953) Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects. U.S. National Institutes of Health.